Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial (vol 400, pg 1585, 2022)

被引：0
|
作者：
Yang, P.
Song, L.
Zhang, Y.
机构：
来源：
LANCET | 2022年 / 400卷 / 10367期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1926 / 1926
页数：1
相关论文
共 29 条
  • [21] Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial (vol 604, pg 645, 2023)
    Wang, Y.
    Li, S.
    Pan, Y.
    [J]. LANCET, 2020, 401 (10382): : 1078 - 1078
  • [22] Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial (vol 401, pg 645, 2023)
    Wang, Y.
    Li, S.
    Pan, Y.
    [J]. LANCET, 2023, 401 (10382): : 1078 - 1078
  • [23] RhPro-UK in acute ischemic stroke within 4.5 h of stroke onset trial-2 (the PROST-2 study): Rationale and design of a multicenter, prospective, randomized, open-label, blinded-endpoint, controlled phase 3 non-inferiority trial
    Li, Shuya
    Gu, Hong-Qiu
    Feng, Baoyu
    Dong, Qiang
    Fan, Dongsheng
    Xu, Yun
    Zhu, Suiqiang
    Wang, Yongjun
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2024,
  • [24] Intensive compared with less intensive blood pressure control to prevent adverse cardiac remodelling in children with chronic kidney disease (HOT-KID): a parallel-group, open-label, multicentre, randomised, controlled trial
    Sinha, Manish D.
    Gu, Haotian
    Douiri, Abdel
    Cansick, Janette
    Finlay, Eric
    Gilbert, Rodney
    Kerecuk, Larissa
    Lunn, Andrew
    Maxwell, Heather
    Morgan, Henry
    Shenoy, Mohan
    Shroff, Rukshana
    Subramaniam, Pushpa
    Tizard, Jane
    Tse, Yincent
    Rezavi, Reza
    Simpson, John M.
    Chowienczyk, Phil J.
    [J]. LANCET CHILD & ADOLESCENT HEALTH, 2023, 7 (01): : 26 - 36
  • [25] Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial (vol 400, pg 1858, 2022)
    Goodall, R. L.
    Meredith, S. K.
    Nunn, A. J.
    [J]. LANCET, 2022, 400 (10365): : 1766 - 1766
  • [26] Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial
    Moniche, Francisco
    Cabezas-Rodriguez, Juan Antonio
    Valverde, Roberto
    Escudero-Martinez, Irene
    Lebrato-Hernandez, Lucia
    Pardo-Galiana, Blanca
    Ainz, Leire
    Medina-Rodriguez, Manuel
    de la Torre, Javier
    Escamilla-Gomez, Virginia
    Ortega-Quintanilla, Joaquin
    Zapata-Arriaza, Elena
    de Alboniga-Chindurza, Asier
    Mancha, Fernando
    Gamero, Miguel-Angel
    Perez, Soledad
    Espinosa-Rosso, Raul
    Forero-Diaz, Lucia
    Moya, Miguel
    Pinero, Pilar
    Calderon-Cabrera, Cristina
    Nogueras, Sonia
    Jimenez, Rosario
    Martin, Vanesa
    Delgado, Fernando
    Ochoa-Sepulveda, Juan-Jose
    Quijano, Blanca
    Mata, Rosario
    Santos-Gonzalez, Monica
    Carmona-Sanchez, Gloria
    Herrera, Concha
    Gonzalez, Alejandro
    Montaner, Joan
    [J]. LANCET NEUROLOGY, 2023, 22 (02): : 137 - 146
  • [27] Effects of intensive lipid lowering compared with moderate-intensity lipid lowering on coronary atherosclerotic plaque phenotype and major adverse cardiovascular events in adults with low to intermediate 10-year ASCVD risk (ILLUMINATION study): protocol for a multicentre, open-label, blinded-endpoint, randomised controlled trial
    Zheng, Jianan
    Hou, Zhihui
    Yuan, Jinqing
    Zhao, Xueyan
    Wang, Yang
    Li, Jia
    Zhang, Wenjia
    Dou, Kefei
    Lu, Bin
    [J]. BMJ OPEN, 2023, 13 (06):
  • [28] Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial (vol 18, pg 672, 2017)
    Garcia-Donas, J.
    Font, A.
    Perez-Valderrama, B.
    [J]. LANCET ONCOLOGY, 2019, 20 (01): : E9 - E9
  • [29] Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2x2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment
    Huang, Yining
    Sharma, Vijay K.
    Robinson, Thompson
    Lindley, Richard I.
    Chen, Xiaoying
    Kim, Jong Sung
    Lavados, Pablo
    Olavarria, Veronica
    Arima, Hisatomi
    Fuentes, Sully
    Huy Thang Nguyen
    Lee, Tsong-Hai
    Parsons, Mark W.
    Levi, Christopher
    Demchuk, Andrew M.
    Bath, Philip M. W.
    Broderick, Joseph P.
    Donnan, Geoffrey A.
    Martins, Sheila
    Pontes-Neto, Octavio M.
    Silva, Federico
    Pandian, Jeyaraj
    Ricci, Stefano
    Stapf, Christian
    Woodward, Mark
    Wang, Jiguang
    Chalmers, John
    Anderson, Craig S.
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2015, 10 (05) : 778 - 788
123